ADC Testing Service On PDX Organoids I Pharmaron CRO

This poster was presented at AACR 2025.

We present a case study showcasing the testing of antibody-drug conjugates (ADC) for efficacy and safety on organoids derived from patient-derived xenograft (PDX) models and organoids derived from healthy intestinal tissue.

This study highlights the platform’s capabilities demonstrated through ADCs that target HER2.

Over 150 PDX organoids from diverse cancer types and normal organoids from intestinal tissue were developed.
HER2 expression was assessed via multi-omics platforms RNAseq, WES, Western blot, and IHC staining.
Organoid viability testing was performed on 14 organoids with varying HER2 levels using four ADCs and their payload and payload+linker controls.
Safety evaluation was conducted using intestinal organoids.

Key findings from ADC Testing on PDX organoids and Intestinal organoids:

Efficacy: High HER2 expression correlated with increased sensitivity to ADC treatment, while lower expression indicated resistance. Payloads alone caused broad cytotoxicity.
Safety: Intestinal organoids showed minimal response to ADCs, revealing a favorable therapeutic window with reduced gastrointestinal side effects.

Download the full poster below to learn more about our ADC testing options in organoids.

Name(Required)

First Last

Company Name(Required)

Job Title(Required)

Country(Required)

State(Required)

Message

Email(Required)

This field is hidden when viewing the form

Lead Source(Required)

By completing and submitting this form, you acknowledge that you have read and understood our Privacy Policy, and you consent to the collection and processing of your personal data by Pharmaron for the purpose of responding to your inquiry. You also agree to be contacted by Pharmaron regarding relevant services and updates. You may withdraw your consent at any time.